-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shi Si Pharmaceutical has been listed among the Top 100 Chinese industrial enterprises in the chemical pharmaceutical industry.
Category:
Time：2020-10-16
On October 13, the 2020 Annual Summit of China’s Chemical Pharmaceutical Industry was successfully held in Nanjing, Jiangsu Province. During the conference, the “2020 List of Outstanding Enterprises and Excellent Product Brands in China’s Chemical Pharmaceutical Industry,” jointly recommended by the China Association of Chemical Pharmaceutical Industry, the China Pharmaceutical Commerce Association, the China Over-the-Counter Drug Association, the China Vaccine Industry Association, and Sinopharm Expo Co., Ltd., was released.
Relying on its strong corporate strength, Shijiazhuang No.4 Pharmaceutical Co., Ltd. has been honored with four prestigious awards: ranked 27th on the “Top 100 Chinese Chemical Pharmaceutical Industry Enterprises in Comprehensive Strength,” recognized as an outstanding export-oriented brand in the Chinese chemical pharmaceutical industry, awarded the title of Excellent Enterprise Brand for Promoting the Integration of Informatization and Industrialization in the Chinese chemical pharmaceutical industry, and named an Outstanding Product Brand in the Chinese chemical pharmaceutical industry for products that regulate water, electrolyte and acid-base balance, as well as mineral and nutritional supplements.
Shijiazhuang No.4 Pharmaceutical takes R&D innovation as its guiding principle and is fully committed to building a robust core product portfolio. Proactively seizing opportunities in the supply-side structural reform and the shift from old to new growth drivers, the company is cultivating new growth areas, continuously strengthening its brand-building efforts, and integrating the excellence performance management model into every stage of product R&D, production, sales, and service. By leveraging technological innovation to drive rapid enterprise development and enhancing product competitiveness through brand building, the company has achieved healthy and rapid growth.
Meanwhile, Shijiazhuang Fourth Pharmaceutical is steadily advancing its internationalization efforts, having cumulatively achieved registration and export sales in 90 countries and regions, with over 200 registered product specifications and varieties. The company firmly holds the leading position among domestic intravenous solution manufacturers in terms of exports, maintaining double-digit growth in export value for eight consecutive years.
During the conference, a launch ceremony was also held for the “2020 Pharmaceutical Industry Blue Book,” compiled by the China Association of Chemical Pharmaceutical Industry. The Blue Book is edited-in-chief by Wen Zaixing, with Pan Guangcheng and Qu Jiguang serving as executive editors-in-chief.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code